Abstract
The majority of studies investigating the molecular pathogenesis and cell biology underlying dystonia have been performed in individuals with primary dystonia. This includes monogenic forms such as DYT1and DYT6 dystonia, and primary focal dystonia which is likely to be multifactorial in origin. In recent years there has been renewed interest in non-primary forms of dystonia including the dystonia-plus syndromes and heredodegenerative disorders. These are caused by a variety of genetic mutations and their study has contributed to our understanding of the neuronal dysfunction that leads to dystonia These findings have reinforced themes identified from study of primary dystonia including abnormal dopaminergic signalling, cellular trafficking and mitochondrial function. In this review we highlight recent advances in the understanding of the dystonia-plus syndromes and heredodegenerative dystonias.
Keywords: Dystonia- plus syndrome, Secondary dystonia, Molecular pathogenesis, Neurodegeneration, Mitochondria
Current Neuropharmacology
Title:Recent Advances in the Molecular Pathogenesis of Dystonia-Plus Syndromes and Heredodegenerative Dystonias
Volume: 11 Issue: 1
Author(s): Catharina Casper, Eirini Kalliolia and Thomas T. Warner
Affiliation:
Keywords: Dystonia- plus syndrome, Secondary dystonia, Molecular pathogenesis, Neurodegeneration, Mitochondria
Abstract: The majority of studies investigating the molecular pathogenesis and cell biology underlying dystonia have been performed in individuals with primary dystonia. This includes monogenic forms such as DYT1and DYT6 dystonia, and primary focal dystonia which is likely to be multifactorial in origin. In recent years there has been renewed interest in non-primary forms of dystonia including the dystonia-plus syndromes and heredodegenerative disorders. These are caused by a variety of genetic mutations and their study has contributed to our understanding of the neuronal dysfunction that leads to dystonia These findings have reinforced themes identified from study of primary dystonia including abnormal dopaminergic signalling, cellular trafficking and mitochondrial function. In this review we highlight recent advances in the understanding of the dystonia-plus syndromes and heredodegenerative dystonias.
Export Options
About this article
Cite this article as:
Casper Catharina, Kalliolia Eirini and T. Warner Thomas, Recent Advances in the Molecular Pathogenesis of Dystonia-Plus Syndromes and Heredodegenerative Dystonias, Current Neuropharmacology 2013; 11 (1) . https://dx.doi.org/10.2174/1570159X11311010005
DOI https://dx.doi.org/10.2174/1570159X11311010005 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Erythropoietin: Cytoprotection in Vascular and Neuronal Cells
Current Drug Targets - Cardiovascular & Hematological Disorders Glycogen Synthase Kinase-3 (GSK-3) Inhibitors for the Treatment of Alzheimers Disease
Current Pharmaceutical Design Glycosaminoglycans, Protein Aggregation and Neurodegeneration
Current Protein & Peptide Science Red Blood Cell-Encapsulated L-Asparaginase: Potential Therapy of Patients with Asparagine Synthetase Deficient Acute Myeloid Leukemia
Protein & Peptide Letters Role of Natural Plant Products Against Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets MicroRNAs: Potential Diagnostic and Therapeutic Targets for Breast Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Platelets in Alzheimer’s Disease-Associated Cellular Senescence and Inflammation
Current Pharmaceutical Design Amyloid-Binding Compounds and their Anti-Prion Potency
Current Topics in Medicinal Chemistry Peptides for Tumour Therapy and Diagnosis: Current Status and Future Directions
Current Medicinal Chemistry Key Role of Mitochondria in Alzheimer’s Disease Synaptic Dysfunction
Current Pharmaceutical Design Advances in Synergistic Combinations of Chinese Herbal Medicine for the Treatment of Cancer
Current Cancer Drug Targets Imatinib Reduces the Vasculogenic Potential of Plastic Tumor Cells
Current Angiogenesis (Discontinued) Potential Clinical Applications of Multi-functional Milk Proteins and Peptides in Cancer Management
Current Medicinal Chemistry Antibody-Drug Conjugate Targets
Current Cancer Drug Targets Non-Cholinergic Pharmacotherapy Approaches to Alzheimers Disease: The Use of Non-Steroidal Anti-Inflammatory Drugs
CNS & Neurological Disorders - Drug Targets Targeting Transcription Factor Binding to DNA by Competing with DNA Binders as an Approach for Controlling Gene Expression
Current Topics in Medicinal Chemistry Animal Models for Testing Anti-Prion Drugs
Current Topics in Medicinal Chemistry Improving the Stability of Aptamers by Chemical Modification
Current Medicinal Chemistry MicroRNAs in Organogenesis and Disease
Current Molecular Medicine Erythropoietin Signaling and Neuroprotection
Current Signal Transduction Therapy